Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 95.95% | -42.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 95.95% | -42.24% | |||
| Cost of Revenue | 339.34% | -60.34% | |||
| Gross Profit | -103.10% | -7.86% | |||
| SG&A Expenses | -99.97% | -45.15% | |||
| Depreciation & Amortization | 0.00% | -1.74% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -67.40% | -45.69% | |||
| Operating Income | 95.52% | 46.23% | |||
| Income Before Tax | -82.60% | 3,105.69% | |||
| Income Tax Expenses | -169.85% | -- | |||
| Earnings from Continuing Operations | -69.12% | 2,703.52% | |||
| Earnings from Discontinued Operations | -77.69% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -70.03% | 3,013.40% | |||
| EBIT | 95.52% | 46.23% | |||
| EBITDA | 99.66% | 47.27% | |||
| EPS Basic | -69.96% | 3,077.78% | |||
| Normalized Basic EPS | 400.00% | 73.33% | |||
| EPS Diluted | -69.96% | 3,077.78% | |||
| Normalized Diluted EPS | 400.00% | 73.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||